Goldenwell Biotech (Goldenwell Biotech) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Goldenwell Biotech Debt-to-Equity?

Goldenwell Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Goldenwell Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Goldenwell Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $0.05 Mil. Goldenwell Biotech's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Goldenwell Biotech's Debt-to-Equity or its related term are showing as below:

During the past 4 years, the highest Debt-to-Equity Ratio of Goldenwell Biotech was 0.16. The lowest was 0.12. And the median was 0.14.

GWLL's Debt-to-Equity is not ranked ^*
in the Consumer Packaged Goods industry.
Industry Median: 0.41
* Ranked among companies with meaningful Debt-to-Equity only.

Goldenwell Biotech Debt-to-Equity Historical Data

The historical data trend for Goldenwell Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goldenwell Biotech Debt-to-Equity Chart

Goldenwell Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.16

0.12

Goldenwell Biotech Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Goldenwell Biotech's Debt-to-Equity

For the Packaged Foods subindustry, Goldenwell Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Goldenwell Biotech's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Goldenwell Biotech's Debt-to-Equity falls into.

Goldenwell Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Goldenwell Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0.085
	=	0.00

Goldenwell Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0.054
	=	0.00

Goldenwell Biotech (OTCPK:GWLL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Goldenwell Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Goldenwell Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Goldenwell Biotech (Goldenwell Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Goldenwell Biotech Inc (OTCPK:GWLL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2071 Midway Drive, Twinsburg, OH, USA, 44087

Website

https://www.goldenwellbiotech.com

Goldenwell Biotech Inc is engaged in the research and development, production and sales of health care and supplements products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.

Executives

Li Yang	director, 10 percent owner, officer: Treasurer	C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Hua Xie	director, officer: Secretary	C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Shuang Liu	director, 10 percent owner, officer: Chief Executive Officer	C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087

Goldenwell Biotech (Goldenwell Biotech) Headlines

No Headlines